---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-001744"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2026-03-13T23:59:59+00:00"
generated_at: "2026-05-15T12:33:16.581061+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences reports 2025 net loss $2.7M, cash $7.9M, advances DNase program

## Summary
- Net loss $2.7M for FY2025; royalty revenue from Takeda sublicense rose 19% to $3.0M.
- R&D expenses decreased 7% to $3.1M (excl. prior-year impairment); G&A down 20% to $2.7M.
- Ended year with $7.9M cash, up $1.7M from prior year-end, aided by $4.0M October public offering.
- Preclinical data supporting DNase I for NETs in cancers; progressing toward IND submission.
- Pursuing strategic alternatives to maximize shareholder value.

## SEC filing metadata
- accession: 0001683168-26-001744
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2026-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/0001683168-26-001744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-001744
- JSON: https://secwatch.observer/filing/0001683168-26-001744.json
- Plain text: https://secwatch.observer/filing/0001683168-26-001744.txt

## Key facts
- Earnings Releases
  Xenetic Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $3.0 million, net income approximately $2.7 million.
  - Period: the year ended December 31, 2025
  - Revenue: $3.0 million
  - Net income: approximately $2.7 million
  - Result: reported results
  source text: investment in the Company’s most promising scientific programs. Royalty revenue from the Company’s sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries. Research and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/0001683168-26-001744-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.